Cancer Res:科学家成功解析癌细胞的神秘调节机制

2018-01-16 佚名 “细胞”微信号

近日,一项刊登在国际杂志Cancer Research上的研究报告中,来自利物浦大学等机构的癌症研究人员通过研究深入解析了癌细胞调节的分子机制,或为后期开发新型癌症疗法提供新的思路和希望。

近日,一项刊登在国际杂志Cancer Research上的研究报告中,来自利物浦大学等机构的癌症研究人员通过研究深入解析了癌细胞调节的分子机制,或为后期开发新型癌症疗法提供新的思路和希望。

研究者Ian Prior表示,这项研究中我们同阿斯利康公司合作重点对人类机体中激酶蛋白进行研究;通过研究我们测定了激酶活性的改变如何影响癌细胞的生长、发育和调节;同时研究人员还测定了癌症患者机体中激酶网络的“线路布置”情况以便后期能够鉴别出有效杀灭癌细胞的更为有效的策略。

相关研究数据或为后期研究者使用激酶来开发新型癌症疗法提供一定的数据支持,目前研究人员已经能够成功以一些激酶为靶点来开发新型癌症疗法,这种疗法能够通过抑制诱发癌细胞分裂和生长的激酶来发挥作用,然而目前研究人员还需要对激酶进行更为深入的研究,从而来阐明其在癌症疗法开发过程中所扮演的关键角色。

Prior教授说道,我们重点对显微镜下的癌细胞行为进行了相关研究,同时我们希望能够理解不同蛋白对癌细胞行为的影响效应;科学家们对激酶的研究已经持续了好多年了,但他们仅仅是将关注点集中于几种类型的激酶上,而对于其它类型激酶的作用机制却知之甚少,这项研究中研究人员就对激酶研究领域被忽略的方向进行了相关研究,同时他们还讨论了当前治疗癌症患者所面临的挑战和成功案例。

相关研究由西北癌症研究机构(North West Cancer Research)提供资助,该机构CEO Alastair Richards表示,作为癌症研究领域的资助机构,我们一直很高兴听到我们的资助能够帮助科学家们在癌症研究领域取得更多的突破。

原始出处:

Wilson LJ,et al.,New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome.Cancer Res. 2018 Jan 1;78(1):15-29.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910921, encodeId=56821910921cc, content=<a href='/topic/show?id=04d99206316' target=_blank style='color:#2F92EE;'>#调节机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92063, encryptionId=04d99206316, topicName=调节机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Wed May 30 20:03:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672875, encodeId=a66516e28752f, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Apr 14 01:03:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252446, encodeId=a2381252446e6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jan 18 05:03:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279438, encodeId=f3a62e943832, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/27/bc9471a1d06ce496224d67ae09f6eddb.jpg, createdBy=e7052205349, createdName=吉吉吧啦, createdTime=Wed Jan 17 19:44:36 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279160, encodeId=d4472e916026, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Jan 16 19:38:43 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1910921, encodeId=56821910921cc, content=<a href='/topic/show?id=04d99206316' target=_blank style='color:#2F92EE;'>#调节机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92063, encryptionId=04d99206316, topicName=调节机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Wed May 30 20:03:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672875, encodeId=a66516e28752f, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Apr 14 01:03:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252446, encodeId=a2381252446e6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jan 18 05:03:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279438, encodeId=f3a62e943832, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/27/bc9471a1d06ce496224d67ae09f6eddb.jpg, createdBy=e7052205349, createdName=吉吉吧啦, createdTime=Wed Jan 17 19:44:36 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279160, encodeId=d4472e916026, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Jan 16 19:38:43 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2018-04-14 hongbochen
  3. [GetPortalCommentsPageByObjectIdResponse(id=1910921, encodeId=56821910921cc, content=<a href='/topic/show?id=04d99206316' target=_blank style='color:#2F92EE;'>#调节机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92063, encryptionId=04d99206316, topicName=调节机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Wed May 30 20:03:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672875, encodeId=a66516e28752f, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Apr 14 01:03:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252446, encodeId=a2381252446e6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jan 18 05:03:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279438, encodeId=f3a62e943832, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/27/bc9471a1d06ce496224d67ae09f6eddb.jpg, createdBy=e7052205349, createdName=吉吉吧啦, createdTime=Wed Jan 17 19:44:36 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279160, encodeId=d4472e916026, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Jan 16 19:38:43 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2018-01-18 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1910921, encodeId=56821910921cc, content=<a href='/topic/show?id=04d99206316' target=_blank style='color:#2F92EE;'>#调节机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92063, encryptionId=04d99206316, topicName=调节机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Wed May 30 20:03:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672875, encodeId=a66516e28752f, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Apr 14 01:03:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252446, encodeId=a2381252446e6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jan 18 05:03:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279438, encodeId=f3a62e943832, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/27/bc9471a1d06ce496224d67ae09f6eddb.jpg, createdBy=e7052205349, createdName=吉吉吧啦, createdTime=Wed Jan 17 19:44:36 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279160, encodeId=d4472e916026, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Jan 16 19:38:43 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2018-01-17 吉吉吧啦

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1910921, encodeId=56821910921cc, content=<a href='/topic/show?id=04d99206316' target=_blank style='color:#2F92EE;'>#调节机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92063, encryptionId=04d99206316, topicName=调节机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Wed May 30 20:03:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672875, encodeId=a66516e28752f, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sat Apr 14 01:03:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252446, encodeId=a2381252446e6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jan 18 05:03:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279438, encodeId=f3a62e943832, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/27/bc9471a1d06ce496224d67ae09f6eddb.jpg, createdBy=e7052205349, createdName=吉吉吧啦, createdTime=Wed Jan 17 19:44:36 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279160, encodeId=d4472e916026, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Jan 16 19:38:43 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2018-01-16 1e0e5697m83(暂无匿称)

    henhao

    0

相关资讯

Nat Chem:癌症荨麻 荨麻:一种治疗癌症的新方法

一种创新的癌症治疗方法利用了荨麻中发现的化合物。 虽然现在还处于初期阶段,但新的治疗方法可以提供更有效,更具体的癌症治疗。

Nature:重磅!这次,饿死癌细胞,真的有希望!

这些年来,饿死癌细胞的言论在网上不断流传。包括浙江大学肿瘤研究所教授胡汛发表在国际生物和医学领域权威杂志《elife》上利用小苏打治疗癌症,以及清华大学颜宁团队在《Nature》上面发表的一篇文章了解清楚GLUT1的组成、结构和工作机理,在后续的新闻发布会上也被不少媒体以“饿死癌细胞”为题迅速引起热议。

Cell:抗癌药RGX-104进入临床试验,可激发免疫系统全力摧毁癌细胞!

基于免疫系统可以被用来检测和杀死癌细胞的原理,很少有癌症治疗产生比免疫治疗药物更多的兴奋,这与在感染性微生物之后进行的方式非常相似。然而这些治疗仅对一些患者有益,并且在绝大多数情况下仍然无效。癌细胞很狡猾,他们有很多方法来保护自己免受冲击。

Cell Rep:阻断癌细胞DNA修复真的很难吗?

发表在《Cell Reports》的一篇文章证明,蛋白质RYBP可以使癌细胞对DNA损伤更敏感

PNAS:重磅级成果!新型糖尿病药物或能促进癌细胞对化疗药物变得更加敏感

近日,一项刊登在国际杂志Proceedings of the National Academy of Sciences上的研究报告中,来自美国达纳-法伯癌症研究所(Dana-Farber Cancer Institute)的研究人员通过研究发现,一种实验性的糖尿病药物或能促进癌细胞对传统化疗药物变得更加敏感,因此将这种糖尿病药物与化疗药物相结合或许有望潜在改善癌症患者的预后表现。

Nat Med:新的生物标记物可预测PD-1疗法效果!

如今基于免疫系统的正常功能靶向作用,免疫疗法可以有效的治疗黑素瘤和肺癌。而特定抑制剂可以激活免疫细胞,使其能够特定的识别癌细胞并消灭它们。免疫疗法可以控制多达50%的患者的癌细胞,在某些情况下甚至可以完全治愈。